Thursday, November 7, 2013

Insulin degludec

Publication date:

Available online 25 October 2013

SOURCE:Primary Care Diabetes

Author(s): Kamlesh Khunti , Xavier Cos , Guy Rutten

Many patients with type 2 diabetes continue to have poor glycaemic control and would benefit from insulin therapy. However, resistance to the introduction of insulin therapy can be high on both the part of the healthcare provider and the patient. A number of new, long-acting basal insulins are in development that provide good metabolic control, but with a lower risk of hypoglycaemia than currently available insulins, and greater flexibility in dosing time from day to day. These attributes may address some of the current barriers to insulin initiation and intensification that currently limit the effectiveness of diabetes care.
Full Post

No comments:

Post a Comment